Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised to a single oral dose of CBD (600 mg) or placebo. Healthy controls (n = 19) were studied under identical conditions but did not receive any drug. Participants were scanned with functional magnetic resonance imaging (fMRI) during a fearful face-processing paradigm. Activation related to the CHR state and to the effects of CBD was examined using a region-of-interest approach. During fear processing, CHR participants receiving placebo (n = 15) showed greater activation than controls (n = 19) in the parahippocampal gyrus but less activation in the striatum. Within these regions, activation in the CHR group that received CBD (n = 15) was intermediate between that of the CHR placebo and control groups. These findings suggest that in CHR patients, CBD modulates brain function in regions implicated in psychosis risk and emotion processing. These findings are similar to those previously evident using a memory paradigm, suggesting that the effects of CBD on medial temporal and striatal function may be task independent.

情绪失调和焦虑在临床精神病高危人群 (CHR) 中很常见，并且与纹状体和颞叶内侧对情绪刺激的神经反应改变有关。使用随机、双盲、平行组设计，33 名 CHR 患者被随机分配至单次口服剂量的 CBD（600 mg）或安慰剂。健康对照组 ( n  = 19) 在相同条件下进行了研究，但未接受任何药物治疗。在可怕的面部处理范例中，使用功能性磁共振成像 (fMRI) 对参与者进行扫描。使用感兴趣区域方法检查与 CHR 状态和 CBD 影响相关的激活。在恐惧处理过程中，接受安慰剂（n  = 15）的 CHR 参与者比对照组表现出更大的激活（n  = 19）在海马旁回，但在纹状体中的激活较少。在这些区域内，接受 CBD 的 CHR 组（n  = 15）的激活介于 CHR 安慰剂组和对照组之间。这些发现表明，在 CHR 患者中，CBD 调节与精神病风险和情绪处理有关的区域的大脑功能。这些发现与之前使用记忆范式的结果相似，表明 CBD 对内侧颞叶和纹状体功能的影响可能与任务无关。